NCT02821468View on ClinicalTrials.gov

Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN

PHASE4UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions
Osteoarthritis, Knee
Interventions
DRUG

Droglican

Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg

DRUG

Paracetamol or oral NSAIDs excluding COX2 inhibitors

Trial Locations (1)

Unknown

RECRUITING

CHU Brugmann, Brussels

Sponsors

Lead Sponsor

Bioiberica

Collaborators (1)

Artialis
All Listed Sponsors
collaborator

Artialis

INDUSTRY

lead

Bioiberica

INDUSTRY